DVT nursing reference: assessment, interventions, and NCLEX tips

Deep vein thrombosis (DVT) is the formation of a blood clot within a deep vein, most often in the lower extremity. DVT affects more than 200,000 Americans annually and carries a 30-day mortality of approximately 6% — rising to 12% when complicated by pulmonary embolism. That complication is what makes DVT a priority condition in nursing: up to 50,000 DVT cases annually progress to PE, a life-threatening emergency. DVT and PE are not separate conditions — they are two expressions of the same disease process, venous thromboembolism (VTE). Understanding DVT is prerequisite knowledge for pulmonary embolism nursing. Every nurse working in med-surg, critical care, ortho, or postoperative settings will encounter DVT regularly, making it high-yield for clinical practice and for NCLEX.

Pathophysiology

DVT formation follows the same pathological model as all venous thromboembolism: Virchow’s triad. In 1856, Rudolf Virchow described three overlapping conditions that together drive thrombus formation in the venous system.

Venous stasis occurs when blood flow slows, allowing platelets and activated clotting factors to accumulate at low-flow sites — particularly behind venous valve pockets in the calf, where the soleal sinuses are a frequent origin point. Prolonged bed rest, immobility from casting or paralysis, long-haul travel, and right-sided heart failure all impair venous return and create stasis conditions.

Hypercoagulability represents an increased systemic tendency toward clotting. Malignancy, pregnancy, oral contraceptive use, inherited thrombophilias (Factor V Leiden, prothrombin G20210A mutation, protein C and S deficiency, antiphospholipid syndrome), and the postoperative state all shift the coagulation-fibrinolysis balance toward clot formation.

Endothelial injury disrupts the normal anticoagulant surface of the vessel wall. Surgery, trauma, IV catheter placement, and prior DVT all expose subendothelial collagen and activate the clotting cascade directly.

Once a thrombus forms, propagation depends on the balance between ongoing coagulation and the body’s fibrinolytic response. Thrombi that extend proximally — from calf veins into the popliteal, femoral, or iliac veins — carry substantially higher risk of embolization. When a thrombus or fragment breaks free, it travels through the right heart and lodges in the pulmonary vasculature, producing pulmonary embolism. This is why proximal DVT is treated with greater urgency than isolated distal (calf) DVT. See the pulmonary embolism nursing reference for the downstream consequences of embolization.

Risk factors

Organizing DVT risk factors by Virchow’s triad makes them easier to retain and apply clinically.

Venous stasis

• Prolonged immobility or bed rest
• Long-haul travel (>4 hours seated)
• Paralysis or lower extremity casting
• Obesity (elevated intra-abdominal pressure impairs venous return)
• Heart failure

Hypercoagulability

• Active malignancy (one of the strongest risk factors — cancer activates tissue factor)
• Pregnancy and the postpartum period
• Combined oral contraceptive pills (estrogen component)
• Hormone replacement therapy (HRT)
• Inherited thrombophilias: Factor V Leiden (most common inherited thrombophilia), prothrombin G20210A mutation, antiphospholipid syndrome, protein C/S deficiency, antithrombin deficiency
• Prior DVT or PE (recurrence risk up to 25%)
• Dehydration (increases blood viscosity)
• Sepsis

Endothelial injury

• Surgery — orthopedic procedures (hip and knee replacement) carry the highest surgical DVT risk
• Trauma
• Central venous catheter placement
• Advanced age (>60 years; vascular changes reduce endothelial integrity)

Clinical presentation

Approximately 50% of DVTs are asymptomatic at the time of diagnosis, discovered incidentally during imaging for another indication. When symptoms are present, they are most often unilateral — bilateral presentation should prompt consideration of an alternative diagnosis such as heart failure or bilateral compression.

Lower extremity DVT symptoms:

• Leg pain or aching, often described as a cramping sensation — reported in ~50% of symptomatic cases
• Swelling of the affected limb — reported in ~70% of symptomatic cases
• Erythema and warmth of the overlying skin
• Distension of superficial veins
• Pitting edema confined to the symptomatic leg

Homan’s sign — calf pain produced by passive dorsiflexion of the foot — was historically taught as a screening maneuver. It has low sensitivity (~50%) and low specificity; both DVT and muscle strains produce a positive result. Current guidelines, including those from the American College of Chest Physicians, do not recommend Homan’s sign as a diagnostic test. It remains on NCLEX because students need to know its limitations.

Phlegmasia cerulea dolens represents severe DVT with massive iliofemoral thrombosis. The entire limb becomes markedly swollen, cyanotic, and painful. It is a vascular emergency with risk of venous gangrene.

Upper extremity DVT (axillary, subclavian, or internal jugular vein) presents with arm swelling, pain, and prominence of superficial veins of the chest wall. It accounts for ~10% of all DVTs and is frequently catheter-related (PICC lines, central venous catheters).

Signs of PE requiring immediate escalation: sudden dyspnea, pleuritic chest pain, tachycardia, drop in O2 saturation, and hemoptysis. Any DVT patient who develops these symptoms must be treated as a potential PE emergency.

Wells score for DVT

The Wells score is the validated pretest probability tool for DVT. Nurses need to understand it for documentation, NCLEX, and clinical communication with providers.

Diagnosis

Compression duplex ultrasound is the gold standard for diagnosing lower extremity DVT. The diagnostic criterion is non-compressibility of the vein — a normal vein collapses completely when external pressure is applied; a vein containing thrombus does not. The test evaluates both anatomy (B-mode imaging) and blood flow (Doppler) and is non-invasive, repeatable, and radiation-free. Proximal veins (popliteal, femoral, iliac) are evaluated in all patients; isolated distal ultrasound (calf veins) is performed when distal DVT is suspected.

D-dimer is a fibrin degradation product elevated whenever clot breakdown is occurring. Its clinical utility is in ruling out DVT in low-probability patients: a negative D-dimer in a patient with a low Wells score effectively excludes DVT without the need for imaging. Its limitation is low specificity — D-dimer is elevated in many conditions including infection, malignancy, pregnancy, surgery, and advanced age, meaning a positive result requires follow-up imaging to confirm DVT.

CT venography is used when pelvic or inferior vena cava (IVC) thrombus is suspected, or when compression ultrasound results are inconclusive. It requires IV contrast and radiation.

MRI venography provides high-resolution imaging of the pelvis, IVC, and upper extremity veins and avoids radiation. It is reserved for complex presentations, pregnancy, and cases where CT contrast is contraindicated.

Nursing assessment

A systematic DVT assessment covers the limb, systemic findings, and PE surveillance.

• Bilateral limb circumference: Measure both legs at a consistent, documented anatomical landmark (typically 10 cm below the tibial tuberosity for calf, and mid-thigh). Asymmetry >3 cm is clinically significant.
• Skin assessment: Erythema, warmth, skin discoloration, venous distension, blistering (in severe cases).
• Pain assessment: Location, character, severity (0–10 scale), aggravating and relieving factors.
• Neurovascular checks: Capillary refill, peripheral pulses, sensation, motor function — particularly for suspected phlegmasia.
• PE surveillance: At every assessment, evaluate for sudden dyspnea, tachycardia, pleuritic chest pain, O2 desaturation, hemoptysis, and anxiety — these require immediate escalation.
• Medication reconciliation: Review current anticoagulants, antiplatelet agents (aspirin, clopidogrel), and NSAIDs before adding new therapy.
• Bleeding risk: Prior GI bleed, intracranial hemorrhage, recent surgery, thrombocytopenia, active hepatic disease.

Medical management and nursing implications

Anticoagulation (first-line)

Anticoagulation is the cornerstone of DVT treatment. It prevents clot propagation and PE while the body’s own fibrinolytic system dissolves the existing thrombus.

Direct oral anticoagulants (DOACs) — rivaroxaban (Xarelto) and apixaban (Eliquis) are first-line for most patients with acute DVT. They do not require INR monitoring, have predictable pharmacokinetics, and have equivalent or superior safety compared to warfarin in clinical trials. Rivaroxaban dosing for DVT: 15 mg twice daily with food for 21 days, then 20 mg once daily. Apixaban: 10 mg twice daily for 7 days, then 5 mg twice daily. Nursing implications: Educate patients that these drugs have no routine monitoring blood test — compliance is critical. Rivaroxaban must be taken with food (affects absorption). Reversal agents: andexanet alfa (for rivaroxaban/apixaban), idarucizumab (for dabigatran).

Warfarin — vitamin K antagonist. INR target 2–3 for DVT. Requires frequent INR monitoring, especially during initiation (warfarin effect is delayed 3–5 days). Because of this delay, warfarin is bridged with LMWH or UFH for the first 5 days, until two consecutive therapeutic INR readings are obtained. Nursing implications: Check INR before each dose. Educate on consistent vitamin K intake (leafy greens affect INR). Reversal: vitamin K (slow reversal) or fresh frozen plasma/prothrombin complex concentrate (immediate reversal for major bleeding).

Low-molecular-weight heparin (LMWH) — enoxaparin (Lovenox) — subcutaneous injection, weight-based dosing (typically 1 mg/kg every 12 hours or 1.5 mg/kg once daily). Preferred in pregnancy (does not cross the placenta) and cancer-associated DVT. Anti-Xa levels used for monitoring in obesity, renal impairment, or pregnancy (not routine in all patients). Nursing implications: Rotate SubQ injection sites (abdomen preferred). Do not expel air bubble before injection. Hold 24 hours before neuraxial anesthesia. Reversal: protamine sulfate (partial reversal only).

Unfractionated heparin (UFH) — IV infusion with aPTT monitoring (therapeutic range typically 60–100 seconds). Used in hemodynamically unstable patients, severe renal failure (CrCl <30 mL/min), or when rapid reversal may be needed. Nursing implications: Monitor aPTT every 6 hours until therapeutic, then every 12–24 hours. Check platelet count every 2–3 days to detect heparin-induced thrombocytopenia (HIT). Reversal: protamine sulfate.

Treatment duration:

• Provoked DVT (identifiable reversible risk factor): 3 months
• Unprovoked DVT: 3–6 months minimum; extended therapy often recommended
• Cancer-associated DVT: ongoing, typically for duration of cancer treatment
• Recurrent DVT or inherited thrombophilia: may require indefinite anticoagulation

Thrombolytics

Catheter-directed thrombolysis (CDT) is reserved for massive iliofemoral DVT with acute limb ischemia, when anticoagulation alone is insufficient to preserve limb viability. Systemic thrombolytics are avoided for DVT alone due to bleeding risk. Nursing implications: Strict bleeding precautions — no IM injections, minimize venipuncture, soft-bristle toothbrush, monitor neurological status, check puncture sites continuously.

IVC filter

Inferior vena cava filters are placed when anticoagulation is absolutely contraindicated (active major bleeding) to prevent PE. Their use has declined as data show no mortality benefit and increased DVT recurrence. They are not standard DVT treatment.

Compression therapy

Graduated compression stockings (30–40 mmHg) reduce the incidence of post-thrombotic syndrome — a chronic venous insufficiency syndrome that affects up to 43% of DVT patients within 2 years. Stockings are applied after the acute phase, once the limb swelling has partially resolved. Do not apply compression stockings during the acute phase of DVT without a specific order.

Nursing interventions

• Elevate the affected extremity 15–30 degrees to promote venous return and reduce edema. Use pillows to support the entire limb, not just the heel.
• Do not massage the affected extremity. Massaging an extremity with active DVT can dislodge the thrombus and trigger PE. This is one of the highest-yield NCLEX teaching points for DVT.
• Ambulation: Early ambulation is encouraged once the patient is therapeutically anticoagulated. Contrary to older practice, bed rest is not required for stable DVT and does not reduce PE risk.
• Sequential compression devices (SCDs): Used for DVT prophylaxis in non-affected or non-DVT patients. Never apply SCDs to a limb with confirmed active DVT — the mechanical compression could mobilize the thrombus.
• Monitor for bleeding with anticoagulant therapy: hematuria (pink or red urine), guaiac-positive or bloody stool, unusual bruising, prolonged bleeding from IV puncture sites, gum bleeding, epistaxis, altered mental status (intracranial hemorrhage). Report to provider immediately.
• Fall prevention: Anticoagulated patients are at high risk for serious injury from falls. Implement fall precautions: bed low and locked, call light within reach, non-slip footwear, assist with ambulation.
• Monitor for PE: At every interaction, assess for sudden onset dyspnea, O2 desaturation, tachycardia, pleuritic chest pain, hemoptysis, or anxiety. These require immediate provider notification and emergency workup.
• IV access: Maintain patent IV access for anticoagulant administration and emergency interventions.

Patient education

Discharge teaching for DVT focuses on anticoagulant compliance, safety, and recognition of complications.

• Take your anticoagulant exactly as prescribed. Missing doses significantly increases clot and PE risk. DOACs have no monitoring blood test — the medication itself is the only protection.
• Know the signs of bleeding: blood in urine or stool, unusual bruising, bleeding gums, prolonged nosebleeds, severe headache, or vision changes. Contact your provider or go to the emergency department immediately.
• Know the signs of PE — call 911 immediately for sudden shortness of breath, chest pain that worsens with breathing, coughing up blood, or heart racing with dizziness.
• Wear compression stockings as directed to reduce long-term leg swelling and prevent post-thrombotic syndrome.
• Stay active. Regular walking and leg exercises improve venous return. Avoid prolonged sitting — take breaks to walk every 1–2 hours during travel.
• Stay hydrated — dehydration increases blood viscosity and clotting risk.
• Avoid aspirin and NSAIDs (ibuprofen, naproxen) unless directed by your provider. These increase bleeding risk when combined with anticoagulants.
• Inform all healthcare providers — including dentists and surgeons — that you are taking anticoagulant medication before any procedure.

DVT prophylaxis

Prevention of DVT in hospitalized patients is a nursing responsibility — a significant portion of hospital-acquired VTE events are preventable with consistent prophylaxis protocols.

Mechanical prophylaxis:

• Sequential compression devices (SCDs) applied to all immobile or bedbound patients on admission. Check that SCDs are plugged in, fitting correctly, and cycling. Remove briefly for ambulation and hygiene; reapply immediately.
• Graduated compression stockings for patients with contraindications to pharmacologic prophylaxis.

Pharmacologic prophylaxis:

• LMWH (enoxaparin 40 mg SubQ once daily) or UFH (5,000 units SubQ every 8–12 hours) per institutional protocol.
• High-risk surgical patients — particularly hip arthroplasty, knee arthroplasty, and hip fracture repair — require extended prophylaxis (10–35 days postoperatively) beyond hospital discharge, per ACCP guidelines.

Behavioral prophylaxis:

• Early ambulation post-operatively — encourage and assist patients to walk as soon as clinically safe.
• Adequate hydration to prevent hemoconcentration.

Nurses’ role in prophylaxis: apply SCDs correctly at admission and maintain them, administer prophylactic anticoagulants on time, document patient ambulation, and escalate if a patient is refusing or unable to comply with the prophylaxis protocol.

NCLEX-style practice questions

Question 1. A nurse is assessing a 68-year-old patient who had a total knee replacement 4 days ago. The patient reports right calf pain and swelling. The nurse measures the right calf circumference as 4.5 cm larger than the left. Using the Wells score for DVT, which criteria are present in this scenario?

A. Active cancer, recent surgery, entire leg swollen B. Recent surgery within 12 weeks, calf swelling >3 cm, localized tenderness C. Paralysis, pitting edema, collateral superficial veins D. Recent surgery, entire leg swollen, alternative diagnosis more likely

Answer: B. Recent surgery within 12 weeks (+1), calf swelling >3 cm vs. the asymptomatic leg (+1), and localized tenderness (+1) give a Wells score of 3 — high probability. Total knee replacement is the highest-risk elective surgery for DVT.

Question 2. A provider orders compression ultrasound for a patient with suspected DVT. The ultrasound technician reports that the femoral vein is “non-compressible.” The nurse should interpret this finding as:

A. Normal — veins should not compress under pressure B. Indicative of venous insufficiency C. Diagnostic of DVT — compression failure confirms thrombus D. Inconclusive — MRI is required to confirm

Answer: C. Non-compressibility of the vein under external pressure is the diagnostic criterion for DVT on compression ultrasound. Normal veins collapse completely; thrombosed veins do not.

Question 3. A nurse is caring for a patient with a confirmed left femoral DVT. Which of the following interventions is contraindicated?

A. Elevating the left leg 20 degrees B. Applying a sequential compression device (SCD) to the left leg C. Encouraging ambulation after anticoagulation is initiated D. Monitoring for sudden dyspnea and O2 desaturation

Answer: B. SCDs must never be applied to a limb with confirmed active DVT — mechanical compression of the clot carries embolization risk. The other three actions are all appropriate interventions.

Question 4. A patient with DVT has been started on warfarin (Coumadin). Four days later, the INR is 1.6 (target 2–3). What is the most appropriate nursing action?

A. Discontinue warfarin and switch to a DOAC B. Continue the current LMWH bridge and notify the provider of the subtherapeutic INR C. Hold the next warfarin dose and recheck INR in 72 hours D. Administer vitamin K to bring the INR into range

Answer: B. Warfarin requires 3–5 days to achieve therapeutic effect. During initiation, LMWH bridging is maintained until two consecutive INR readings are therapeutic (2–3). A subtherapeutic INR on day 4 is expected; the bridge should continue and the provider should be notified so dosing can be adjusted.

Question 5. A patient treated for DVT with rivaroxaban develops heavy rectal bleeding in the hospital. The nurse anticipates the provider will order which reversal agent?

A. Protamine sulfate B. Vitamin K C. Andexanet alfa D. Fresh frozen plasma

Answer: C. Andexanet alfa (Andexxa) is the specific reversal agent for rivaroxaban and apixaban (Factor Xa inhibitors). Protamine sulfate reverses heparin and LMWH (partially). Vitamin K reverses warfarin. Fresh frozen plasma provides clotting factors and may be used as an adjunct but is not specific to DOACs.

Question 6. A nurse is teaching a patient newly diagnosed with DVT. Which statement indicates that further teaching is needed?

A. “I should call 911 if I suddenly feel short of breath or have chest pain.” B. “I should massage my leg to help the clot dissolve faster.” C. “I need to take my blood thinner at the same time every day.” D. “I should tell my dentist that I am taking a blood thinner before any dental work.”

Answer: B. Massaging the affected extremity is contraindicated in DVT because it can dislodge the thrombus and cause PE. The other three statements are all correct and reflect appropriate patient understanding.

Sources: Kesieme E et al. Deep Vein Thrombosis: A Clinical Review. StatPearls (NCBI Bookshelf NBK507708); American College of Chest Physicians (ACCP) Antithrombotic Therapy for VTE Guidelines (9th edition); American Society of Hematology 2020 Guidelines for Management of VTE; Wells PS et al. Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis. NEJM 2003.